Home World News FDA Approves Daratumumab and Hyaluronidase-fihj for High-Risk Smoldering Multiple Myeloma World News FDA Approves Daratumumab and Hyaluronidase-fihj for High-Risk Smoldering Multiple Myeloma By Ogkologos - November 13, 2025 476 0 Facebook Twitter Google+ Pinterest WhatsApp Evidence for efficacy is based on the results from the AQUILA study Source RELATED ARTICLESMORE FROM AUTHOR Can ctDNA guide treatment intensification in EGFR mutated non-small cell lung cancer? How to select adjuvant endocrine therapy for postmenopausal women with HR-positive early breast cancer? EMA Recommends Extension of Therapeutic Indications for Abiraterone Acetate MOST POPULAR ESMO Calls on the European Commission to Fund Cancer Research and... September 23, 2026 Obesity and Alcohol Are Contributing to Increases in Bowel Cancer Rates... January 29, 2024 A Combination of Savolitinib and Osimertinib Prolongs PFS in Patients with... January 16, 2026 ESMO Congress 2022, 9-13 September August 22, 2022 Load more HOT NEWS Long-Term Outcomes Suggest a Sustained Clinical Benefit to Metastasis-Directed Treatment Over... EMA Recommends Extension of Therapeutic Indications for Nivolumab and Ipilimumab Cancer Researchers Bring Tools, Experience to COVID-19 Studies Imetelstat Shows Durable Transfusion Independence and Disease-Modifying Activity in Heavily Transfused...
